Brokerages Set Oscar Health, Inc. (NYSE:OSCR) Price Target at $20.78

Shares of Oscar Health, Inc. (NYSE:OSCR) have been given a consensus rating of “Hold” by the twelve research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $20.7778.

A number of equities analysts have issued reports on OSCR shares. Wells Fargo & Company set a $20.00 target price on Oscar Health and gave the stock an “equal weight” rating in a report on Thursday, June 4th. Weiss Ratings upgraded Oscar Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, July 10th. Wall Street Zen raised Oscar Health from a “buy” rating to a “strong-buy” rating in a research report on Sunday, June 14th. Jefferies Financial Group upgraded Oscar Health from an “underperform” rating to a “hold” rating and increased their price objective for the stock from $10.00 to $16.00 in a report on Monday, April 20th. Finally, Wolfe Research started coverage on Oscar Health in a research report on Tuesday, May 5th. They issued a “peer perform” rating on the stock.

Insider Transactions at Oscar Health

In other news, Director Mario Schlosser sold 880,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $29.38, for a total transaction of $25,854,400.00. Following the completion of the transaction, the director directly owned 480,866 shares of the company’s stock, valued at $14,127,843.08. This trade represents a 64.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Mark T. Bertolini sold 624,244 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $28.48, for a total transaction of $17,778,469.12. Following the transaction, the chief executive officer owned 7,751,570 shares of the company’s stock, valued at $220,764,713.60. The trade was a 7.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 3,662,466 shares of company stock worth $105,145,815. Insiders own 22.64% of the company’s stock.

Hedge Funds Weigh In On Oscar Health

A number of large investors have recently modified their holdings of OSCR. Vanguard Group Inc. increased its position in shares of Oscar Health by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 20,701,250 shares of the company’s stock valued at $297,477,000 after acquiring an additional 540,851 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its position in Oscar Health by 11.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,217,816 shares of the company’s stock valued at $132,461,000 after purchasing an additional 910,320 shares during the last quarter. Morgan Stanley boosted its position in Oscar Health by 42.8% during the fourth quarter. Morgan Stanley now owns 6,814,046 shares of the company’s stock valued at $97,918,000 after purchasing an additional 2,043,758 shares during the last quarter. Thrive Capital Management LLC grew its stake in Oscar Health by 33.4% in the fourth quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company’s stock valued at $85,258,000 after purchasing an additional 1,588,395 shares in the last quarter. Finally, BIT Capital GmbH increased its position in shares of Oscar Health by 545.0% during the 4th quarter. BIT Capital GmbH now owns 6,186,267 shares of the company’s stock worth $88,897,000 after purchasing an additional 5,227,152 shares during the last quarter. 75.70% of the stock is currently owned by institutional investors and hedge funds.

Oscar Health Stock Performance

Shares of OSCR opened at $29.05 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.11 and a current ratio of 1.11. Oscar Health has a twelve month low of $10.69 and a twelve month high of $33.10. The firm’s 50 day moving average price is $26.92 and its two-hundred day moving average price is $18.95. The firm has a market cap of $8.76 billion, a P/E ratio of -49.24, a PEG ratio of 1.63 and a beta of 2.34.

Oscar Health (NYSE:OSCR) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.96. Oscar Health had a negative net margin of 0.30% and a negative return on equity of 3.26%. The company had revenue of $4.65 billion during the quarter, compared to the consensus estimate of $4.90 billion. During the same quarter in the prior year, the firm earned $0.92 earnings per share. The firm’s revenue was up 52.6% compared to the same quarter last year. On average, analysts forecast that Oscar Health will post 0.59 EPS for the current fiscal year.

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.